巴克斯德罗斯塔特:一种用于治疗耐药高血压的新型阿尔多氨酸合成酶抑制剂
Sonia Dogra1, Swara Shah1, Lucas Gitzel1
1Department of Medicine, Lehigh Valley Health Network, Allentown, PA.
Current problems in cardiology
|July 3, 2023
概括
抗性高血压影响了许多人,但像Baxdrostat这样的阿尔多氨酸合成酶抑制剂显示出有前途. 这种新药类通过降低阿尔多激素有效降低血压,为更好的高血压管理提供了希望.
科学领域:
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 高血压是一个广泛的全球健康问题,影响超过30%的人口.
- 它是全球首要可预防的死亡风险因素.
- 目前的治疗方法在不到20%的患者中实现了血压控制,这突显了未满足的医疗需求.
研究的目的:
- 审查用于高血压治疗的新型类型的阿尔多合成酶抑制剂 (ASI).
- 专注于Baxdrostat,这是一个强大的ASI在临床试验的第三阶段.
- 探索巴克斯德罗斯塔特在治疗失控高血压,慢性脏疾病和原发性阿尔多斯特主义方面的潜力.
主要方法:
- 关于阿尔多氨酸合成酶抑制剂和Baxdrostat的现有文献的审查.
- 对Baxdrostat的疗效和安全性进行临床前和临床试验数据的分析.
- 讨论ASI作用的生化机制.
主要成果:
- 阿尔多氨酸合成酶抑制剂通过抑制阿尔多氨酸合成酶,有效降低阿尔多氨酸的产生.
- 巴克斯德罗斯塔特在动物和人类研究中显示出显著的降血压效应.
- 早期的数据表明,在特定患者群体中,包括耐性高血压和原发性阿尔多斯特隆症患者中,可能有潜在的益处.
结论:
- 阿尔多氨酸合成酶抑制剂,特别是巴克斯德罗斯塔特,代表了对高血压的有希望的新治疗途径.
- 巴克斯德罗斯塔特的向机制为管理难以控制的血压提供了一种新的方法.
- 进一步的研究和临床试验对于确定巴克斯德罗斯塔特的全部治疗潜力至关重要.
更多相关视频
10:09Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
Published on: August 4, 2022
3.2K
04:37Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
170
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
01:25Antihypertensive Drugs: Direct Renin Inhibitors
699
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
699
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
786
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
786
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
651
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
651
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
698
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
698
01:22Heart Failure Drugs: Diuretics
424
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
424